FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

episode

Lung Cancer Considered not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

NPR News: 09-13-2026 6PM EDT 4 min · 13 Sep 2026 · NPR News Now

Guenther Steiner's 2026 Madrid GP Recap! | Vankah Hours S3E18 1h 11m · 13 Sep 2026 · The Red Flags Podcast

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

Report any issue

Source

Recorded02 Apr 2024

Publisherfeeds.soundcloud.com ↗

Handlerec:2151491

Show notes

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in